Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
The surveillance of antiviral-resistant viruses is important for public health authorities and clinicians to control influenza. Here, we improved fluorescence-based and chemiluminescence-based neuraminidase (NA) inhibition assays for determining influenza susceptibility to NA inhibitors, oseltamivir, zanamivir, peramivir and laninamivir. Then we established a cell-based screening system to evaluate the susceptibility of influenza viruses to a novel antiviral drug, favipiravir, a viral RNA-dependent RNA polymerase inhibitor.
|